Voya Investment Management LLC reduced its holdings in shares of Align Technology, Inc. (NASDAQ:ALGN) by 12.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,886 shares of the medical equipment provider’s stock after selling 7,509 shares during the quarter. Voya Investment Management LLC owned 0.07% of Align Technology worth $9,930,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in ALGN. Squar Milner Financial Services LLC lifted its holdings in shares of Align Technology by 115.4% during the 3rd quarter. Squar Milner Financial Services LLC now owns 168 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 90 shares in the last quarter. Ossiam acquired a new position in shares of Align Technology during the second quarter worth about $43,000. TRUE Private Wealth Advisors purchased a new stake in shares of Align Technology in the second quarter worth about $45,000. CSat Investment Advisory L.P. boosted its position in shares of Align Technology by 218.7% in the second quarter. CSat Investment Advisory L.P. now owns 239 shares of the medical equipment provider’s stock worth $65,000 after buying an additional 164 shares during the period. Finally, FTB Advisors Inc. grew its stake in shares of Align Technology by 102.9% in the second quarter. FTB Advisors Inc. now owns 278 shares of the medical equipment provider’s stock valued at $76,000 after buying an additional 141 shares in the last quarter. Institutional investors own 82.00% of the company’s stock.
Shares of NASDAQ ALGN opened at $276.36 on Wednesday. Align Technology, Inc. has a fifty-two week low of $169.84 and a fifty-two week high of $334.64. The business has a 50 day moving average price of $253.36 and a two-hundred day moving average price of $239.25. The company has a quick ratio of 1.62, a current ratio of 1.73 and a debt-to-equity ratio of 0.03. The firm has a market cap of $21.62 billion, a PE ratio of 56.17, a price-to-earnings-growth ratio of 2.43 and a beta of 2.08.
In related news, Director Warren S. Thaler sold 1,942 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $250.84, for a total value of $487,131.28. Following the completion of the sale, the director now directly owns 43,900 shares of the company’s stock, valued at $11,011,876. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Yuval Shaked sold 500 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $260.25, for a total value of $130,125.00. Following the sale, the director now owns 841 shares in the company, valued at approximately $218,870.25. The disclosure for this sale can be found here. Insiders sold 26,199 shares of company stock worth $6,787,761 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.
ALGN has been the topic of several analyst reports. BidaskClub upgraded Align Technology from a “hold” rating to a “buy” rating in a report on Monday, October 21st. Zacks Investment Research raised shares of Align Technology from a “sell” rating to a “hold” rating and set a $262.00 price objective for the company in a research report on Friday, October 25th. Stifel Nicolaus lifted their price objective on shares of Align Technology from $290.00 to $305.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Bank of America boosted their target price on shares of Align Technology from $220.00 to $240.00 and gave the stock a “neutral” rating in a research report on Thursday, October 24th. Finally, Barclays decreased their target price on shares of Align Technology from $300.00 to $272.00 and set an “overweight” rating for the company in a research note on Monday, October 7th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $253.58.
Align Technology Profile
Align Technology, Inc, a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontics, and restorative and aesthetic dentistry worldwide. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as compliance indicators and compensation for tooth eruption; Invisalign Assist treatment, which offers support to dental practitioners throughout the treatment process, including progress tracking; and Invisalign First Phase I and Invisalign First Comprehensive Phase II package for younger patients with early mixed dentition with a mixture of primary/baby and permanent teeth.
Featured Article: The mechanics of the bid-ask spread in trading
Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN).
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.